REMS: When Approval Comes With Conditions

A Risk Evaluation and Mitigation Strategy (REMS) is a safety programme FDA can require as a condition of approval, where the agency concludes that labelling alone is not enough to keep a product's benefits ahead of its risks.

FDA has had this authority since the FDA Amendments Act of 2007.

A REMS is not a warning. It is machinery: enrolment systems, certification of prescribers and pharmacies, documented safe-use conditions, and an obligation to prove the whole thing works.

The elements

Medication Guide or patient package insert. Information FDA requires to reach the patient directly.

Communication plan. Materials directed at healthcare providers, such as letters to professional societies.

Elements to Assure Safe Use (ETASU). The demanding tier, and the one that changes how a product is distributed. Any of:

• Prescribers must be specially certified.
• The product is dispensed only in certain settings, such as a hospital.
• Dispensing requires evidence of safe-use conditions, such as a documented laboratory result.
• Each patient is subject to monitoring.
• Each patient is enrolled in a registry.

Implementation system. How the sponsor monitors and enforces the ETASU across the distribution chain.

Timetable for submission of assessments. You report to FDA on whether the REMS is meeting its goals.

Why it is a commercial constraint, not just a safety one

An ETASU REMS changes who can prescribe your product and where it can be dispensed. That has direct consequences for uptake, for the sales model, and for the burden you place on a prescriber choosing between your product and one without a REMS.

It also creates a permanent operational obligation. The registry, the certification programme and the assessment reporting all continue for as long as the REMS does.

Modification and removal

A REMS is not permanent. Sponsors can propose modifications, and FDA can require them. Where post-marketing experience shows the risk is better understood or the programme is not adding safety, a REMS can be reduced or released entirely, and many have been.

Shared system REMS

Where a REMS applies to a class, generic applicants may be required to join a single shared system rather than operate a parallel one. This has been a recurring source of dispute, because access to the brand's REMS materials can become a barrier to generic entry, and Congress addressed it in the CREATES Act.